查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403392

中和抗體市場至2030年的預測：按抗體類型、配銷通路、應用、最終用戶和地區進行的全球分析

Neutralizing Antibody Market Forecasts to 2030 - Global Analysis By Antibody Type, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球中和抗體市場規模為 1,904 億美元，預計在預測期內年複合成長率為 10.6%，到 ​​2030年將達到 3,854 億美元。

免疫系統產生一種稱為中和抗體的抗體。這些抗體目的是選擇性地靶向並抑制細菌和病毒等病原體的作用。這些抗體透過與病原體表面的特定區域結合來阻止病原體感染或傷害宿主細胞。這些抗體透過阻止病原體進入細胞和繁殖來幫助免疫系統管理和治癒感染。

根據 GLOBOCAN2020 報告，全球將有 1,930 萬人新診斷出癌症，約 1,000 萬人將死於癌症。

感染疾病增加

肝炎、HIV/AIDS和呼吸道感染疾病感染疾病在世界各地仍然相當普遍。控制這些疾病的一個有前途的治療策略是使用中和抗體。隨著這些感染疾病發生率的上升，對中和抗體的需求應該會越來越大。此外，由於自體免疫疾病盛行率的上升，預計市場將會擴大。

監管挑戰

新型抗體療法要獲得監管部門的批准，需要對其安全性和有效性進行徹底評估。監管機構通常需要全面的臨床資料，這可能會延長開發時間並增加成本。公司可能難以適應法規環境，尤其是包括獨特且複雜的中和抗體時。市場可能會受到監管問題的嚴重限制。

改進抗體工程和設計

抗體工程和設計方法的不斷進步能夠生產最佳化的中和抗體。親和性成熟和抗體人源化是用於提高抗體安全性、半衰期和功效的兩種技術。抗體片段和抗體藥物複合體等新平台的添加增加了治療藥物開發的潛力。這是市場拓展的主要因素。

開發和治療成本高

創建和製造中和抗體的過程既昂貴又耗時。高開發成本是由於大量的研發活動、臨床試驗和製造成本。此外，中和抗體療法非常昂貴，這可能會限制獲得治療的機會，特別是在預算和資源匱乏的醫療保健系統中。

COVID-19 的影響：

中和抗體市場受到了 COVID-19 大流行的嚴重影響。中和抗體對於治療和預防 COVID-19 非常重要。幾種單株抗體療法已批准或授權使用於緊急情況。由於對 SARS-CoV-2 中和抗體的需求迅速增加，該市場顯著成長。

單株抗體領域預計將成為預測期內最大的市場

單株抗體細分市場預計將成為預測期內最大的細分市場。對單株抗體產品的需求，不斷擴大的製藥和生物技術領域以及醫療保健行業豐富的基礎設施的可用性預計將推動單株抗體市場的成長。由於對更先進、更複雜的製造系統的需求不斷成長以及政府對醫療基礎設施現代化的大量投資，醫療保健產業新興國家迅速擴張。

研究機構領域預計在預測期內年複合成長率最高

預計研究機構部門在預測期內的年複合成長率最高。由於癌症和其他慢性疾病的發生率在預期時間內增加，一些組織加強其研究方案並利用收到的資金來開發新技術。研究機構利用公共或商業性資金對目前或未來的產品進行研究，這些產品可用於診斷、治療或監測任何人類疾病。

佔比最大的地區：

由於存在標準的國家醫療保健系統和重要公司的存在，預計北美在預測期內將佔據最大的市場佔有率。在製造業中採用尖端基因工程技術、先進的醫療保健系統、政府對感染控制和管理的支持以及與久坐生活方式相關的疾病盛行率的上升，推動市場的成長。

年複合成長率最高的地區：

預計亞太地區在預測期內將維持最高的年複合成長率。促進市場擴張的因素包括對功能改進的遺傳平台的技術需求不斷增加、基因組學領域研發活動的擴大以及患者對單株抗體（mAb）療法潛在益處的認知的提高。研究和開發行業的擴張以及單株抗體生產的技術進步也支持了市場的成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球中和抗體市場：按抗體類型

  • 單株抗體
  • 多克隆抗體
  • 廣泛中和抗體
  • 交叉中和抗體
  • 其他類型的抗體

第6章 全球中和抗體市場：依目標病毒分類

  • SARS-CoV-2
  • 流感
  • HIV
  • 伊波拉
  • C型肝炎
  • 茲卡熱
  • 其他目標病毒

第7章 全球中和抗體市場：依配銷通路

  • 代理銷售
  • 網路零售

第8章 全球中和抗體市場：依應用分類

  • 診斷
  • 治療
  • 研究與開發
  • 其他用途

第9章 全球中和抗體市場：依最終用戶分類

  • 醫院
  • 製藥公司
  • 實驗室
  • 其他最終用戶

第10章 全球中和抗體市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • GlaxoSmithKline plc
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • Sanofi SA
  • AstraZeneca PLC
  • Merck & Co.Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • Johnson & Johnson
  • BioNTech SE
  • CSL Limite
  • Sinovac Biotech Ltd
  • HaemaLogiX Ltd
Product Code: SMRC24617

According to Stratistics MRC, the Global Neutralizing Antibody Market is accounted for $190.4 billion in 2023 and is expected to reach $385.4 billion by 2030 growing at a CAGR of 10.6% during the forecast period. The immune system produces a kind of antibody known as neutralizing antibodies, which are designed to selectively target and inhibit the action of pathogens like bacteria or viruses. These antibodies stop pathogens from infecting or harming host cells by binding to particular areas, frequently on their surface. These antibodies aid the immune system in managing and curing the infection by blocking the pathogen's capacity to enter cells or multiply.

According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market.

Market Dynamics:

Driver:

Rising numbers of infectious diseases

Infectious disorders including hepatitis, HIV/AIDS, and respiratory infections are still quite common around the world. A promising therapeutic strategy for the management of these illnesses is the use of neutralizing antibodies. Neutralizing antibodies should become more and more in demand as the incidence of these infectious illnesses rises. Furthermore, it is anticipated that the market would rise in response to the rising prevalence of autoimmune illnesses.

Restraint:

Regulatory challenges

Securing regulatory clearance for novel antibody treatments necessitates thorough assessments of their safety and effectiveness. Comprehensive clinical data is frequently required by regulatory bodies, which might result in lengthier development times and higher costs. Companies may find it difficult to navigate the regulatory environment, particularly when it comes to unique or complicated neutralizing antibodies. The market may be severely constrained by regulatory issues.

Opportunity:

Improvements in antibody engineering and design

Neutralizing antibodies that are optimized can be produced thanks to the ongoing advancements in antibody engineering and design approaches. Affinity maturation and antibody humanization are two techniques used to improve the safety, half-life, and effectiveness of antibodies. Adding new platforms to the mix, including antibody fragments and antibody-drug conjugates, increases the potential for developing therapeutics. This is the main factor driving the market's expansion.

Threat:

Expensive development and treatment costs

The process of creating and producing neutralizing antibodies is expensive and time-consuming. High development costs can be attributed to the considerable research and development activities, clinical trials, and manufacturing expenses. Furthermore, neutralizing antibody therapies might be prohibitively expensive, which may restrict accessibility, especially in healthcare systems with tight budgets and resources.

COVID-19 Impact:

The neutralizing antibody market has been significantly influenced by the COVID-19 pandemic. In order to treat and prevent COVID-19, neutralizing antibodies have been essential. Several monoclonal antibody treatments have been approved or authorized for usage in emergency situations. The market has grown significantly as a result of the spike in demand for neutralizing antibodies against SARS-CoV-2.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to be the largest during the forecast period. The need for goods containing monoclonal antibodies, the expansion of the pharmaceutical and biotechnology sectors, and the availability of enhanced infrastructure for the healthcare industry are all anticipated to fuel the growth of the monoclonal antibody market. The healthcare industry is expanding quickly in emerging countries as a result of the rising need for more advanced sophisticated manufacturing systems and large government investments to modernize healthcare infrastructure.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period, owing to the increased incidence of cancer and other chronic illnesses within the anticipated time frame, several organizations have enhanced their research protocols and utilized the funds received to create novel technologies. Funded by public or commercial sources, research institutes conduct investigations on current or forthcoming products that have the potential to be utilized for the diagnosis, treatment, or surveillance of any human ailment.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the presence of a standard nationwide healthcare system and the existence of significant critical companies. The employment of cutting-edge genetic engineering technology in manufacturing, a sophisticated healthcare system, government support for infection control and management, and a rise in the prevalence of diseases associated with sedentary lifestyles are some of the factors driving the market's growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Factors driving the market expansion include the rise in technical demand for genetic platforms with improved capabilities, the expansion of research and development activities in the field of genomics, and the growing awareness among patients about the potential benefits of monoclonal antibodies (mAb) therapy. The market's growth is also fueled by the expansion of the R&D industry and technical advancements in the manufacturing of monoclonal antibodies.

Key players in the market:

Some of the key players in Neutralizing Antibody market include GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Merck & Co.Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., Johnson & Johnson, BioNTech SE, CSL Limite, Sinovac Biotech Ltd and HaemaLogiX Ltd.

Key Developments:

In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.

In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

Antibody Types Covered:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Broadly Neutralizing Antibody
  • Cross Neutralizing Antibody
  • Other Antibody Types

Target Viruses Covered:

  • SARS-CoV-2
  • Influenza
  • HIV
  • Ebola
  • Hepatitis C
  • Zika
  • Other Target Viruses

Distribution Channels Covered:

  • Distributors
  • Online Retail

Applications Covered:

  • Diagnostics
  • Therapeutics
  • Research & Development
  • Other Applications

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neutralizing Antibody Market, By Antibody Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Polyclonal Antibodies
  • 5.4 Broadly Neutralizing Antibody
  • 5.5 Cross Neutralizing Antibody
  • 5.6 Other Antibody Types

6 Global Neutralizing Antibody Market, By Target Virus

  • 6.1 Introduction
  • 6.2 SARS-CoV-2
  • 6.3 Influenza
  • 6.4 HIV
  • 6.5 Ebola
  • 6.6 Hepatitis C
  • 6.7 Zika
  • 6.8 Other Target Viruses

7 Global Neutralizing Antibody Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Distributors
  • 7.3 Online Retail

8 Global Neutralizing Antibody Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostics
  • 8.3 Therapeutics
  • 8.4 Research & Development
  • 8.5 Other Applications

9 Global Neutralizing Antibody Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Laboratories
  • 9.5 Other End Users

10 Global Neutralizing Antibody Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GlaxoSmithKline plc
  • 12.2 Novartis AG
  • 12.3 Regeneron Pharmaceuticals, Inc.
  • 12.4 Roche Holding AG
  • 12.5 Eli Lilly and Company
  • 12.6 Sanofi SA
  • 12.7 AstraZeneca PLC
  • 12.8 Merck & Co.Inc.
  • 12.9 Pfizer Inc.
  • 12.10 Takeda Pharmaceutical Company Limited
  • 12.11 Moderna, Inc.
  • 12.12 Johnson & Johnson
  • 12.13 BioNTech SE
  • 12.14 CSL Limite
  • 12.15 Sinovac Biotech Ltd
  • 12.16 HaemaLogiX Ltd

List of Tables

  • Table 1 Global Neutralizing Antibody Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neutralizing Antibody Market Outlook, By Antibody Type (2021-2030) ($MN)
  • Table 3 Global Neutralizing Antibody Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Neutralizing Antibody Market Outlook, By Polyclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Neutralizing Antibody Market Outlook, By Broadly Neutralizing Antibody (2021-2030) ($MN)
  • Table 6 Global Neutralizing Antibody Market Outlook, By Cross Neutralizing Antibody (2021-2030) ($MN)
  • Table 7 Global Neutralizing Antibody Market Outlook, By Other Antibody Types (2021-2030) ($MN)
  • Table 8 Global Neutralizing Antibody Market Outlook, By Target Virus (2021-2030) ($MN)
  • Table 9 Global Neutralizing Antibody Market Outlook, By SARS-CoV-2 (2021-2030) ($MN)
  • Table 10 Global Neutralizing Antibody Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 11 Global Neutralizing Antibody Market Outlook, By HIV (2021-2030) ($MN)
  • Table 12 Global Neutralizing Antibody Market Outlook, By Ebola (2021-2030) ($MN)
  • Table 13 Global Neutralizing Antibody Market Outlook, By Hepatitis C (2021-2030) ($MN)
  • Table 14 Global Neutralizing Antibody Market Outlook, By Zika (2021-2030) ($MN)
  • Table 15 Global Neutralizing Antibody Market Outlook, By Other Target Viruses (2021-2030) ($MN)
  • Table 16 Global Neutralizing Antibody Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Neutralizing Antibody Market Outlook, By Distributors (2021-2030) ($MN)
  • Table 18 Global Neutralizing Antibody Market Outlook, By Online Retail (2021-2030) ($MN)
  • Table 19 Global Neutralizing Antibody Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Neutralizing Antibody Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 21 Global Neutralizing Antibody Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 22 Global Neutralizing Antibody Market Outlook, By Research & Development (2021-2030) ($MN)
  • Table 23 Global Neutralizing Antibody Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Neutralizing Antibody Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Neutralizing Antibody Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 26 Global Neutralizing Antibody Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 27 Global Neutralizing Antibody Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 28 Global Neutralizing Antibody Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.